Cort Corwin v. ViewRay, Inc.

CourtCourt of Appeals for the Sixth Circuit
DecidedSeptember 1, 2022
Docket21-3863
StatusUnpublished

This text of Cort Corwin v. ViewRay, Inc. (Cort Corwin v. ViewRay, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Sixth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Cort Corwin v. ViewRay, Inc., (6th Cir. 2022).

Opinion

NOT RECOMMENDED FOR PUBLICATION File Name: 22a0363n.06

No. 21-3863

UNITED STATES COURT OF APPEALS FOR THE SIXTH CIRCUIT

FILED ) Sep 01, 2022 PLYMOUTH COUNTY RETIREMENT ) DEBORAH S. HUNT, Clerk ASSOCIATION, Individually and on Behalf of All ) Others Similarly Situated, ) Plaintiff-Appellant, ) ON APPEAL FROM THE ) UNITED STATES DISTRICT v. ) COURT FOR THE ) NORTHERN DISTRICT OF VIEWRAY, INC.; SCOTT DRAKE; AJAY ) OHIO BANSAL; JAMES F. DEMPSEY; CHRIS A. ) RAANES; SHAHRIAR MATIN, ) Defendants-Appellees. ) )

Before: NORRIS, SUHRHEINRICH, and CLAY, Circuit Judges.

SUHRHEINRICH, Circuit Judge. Plymouth County Retirement Association appeals the

dismissal of its complaint in this securities-fraud action against ViewRay, Inc., and some of its

officers. Because Plymouth failed to meet its hefty pleading burden under the Private Securities

Litigation Reform Act and Federal Rule of Civil Procedure 9(b), we affirm.

I.

ViewRay’s Business. ViewRay designs, manufactures, and markets the Linac MRIdian, a

machine that images and treats cancer simultaneously using MRI-guided radiation. The MRIdian

can distinguish between types of soft tissue and thus deliver radiation more accurately, reducing

collateral damage to healthy tissue. Nearly all of ViewRay’s revenue comes from sales of the

MRIdian. No. 21-3863, Plymouth Cnty. Ret. Ass’n v. ViewRay, Inc., et al.

Each MRIdian system costs about $6 million, a cost that’s substantially more than

radiation-therapy systems lacking the MRI feature, but about the same as those with it. That sticker

price comes with other costs too. Typically, a customer needs between nine and fifteen months

after ordering an MRIdian to construct and prepare the room in which it’ll be installed—called a

“vault” in industry jargon. R. 55 at 1264–65 ¶ 36. Installation of the machine in the vault usually

takes another 60 to 90 days. All told, the time from contract-signing to installation is usually

between 12 and 18 months. However, due to the complicated nature of this sale, ViewRay is often

left to “mov[e] at [its] customers’ pace”—which could extend the process even further. Id. at 1293

¶ 115.

ViewRay went public in July 2015. Since then, the company has largely operated at a loss

and has raised capital to fund its operations. ViewRay held two public offerings of stock during

the alleged class period, raising about $173 million in August 2018 and about $150 million in

December 2019.

ViewRay’s Marketing and Backlog. ViewRay sells the MRIdian in the United States and

abroad. In the United States, ViewRay sells through a direct sales force. Abroad, ViewRay

primarily uses third-party distributors supported by ViewRay employees. To estimate future

revenue from MRIdian orders, ViewRay uses a “backlog” to track “all orders for which ViewRay

has not recognized revenue and that ViewRay considers ‘valid.’” Id. at 1254 ¶ 3.

Plymouth’s theories of fraud center on this backlog. Simply stated, Plymouth claims that

ViewRay misled investors by failing to follow the publicly disclosed criteria for determining which

orders to include in the backlog, which thereby inflated the backlog with orders that didn’t belong;

because ViewRay did not disclose to investors that it failed to follow the backlog criteria, those

omissions were misleading given ViewRay’s other disclosures about the backlog.

-2- No. 21-3863, Plymouth Cnty. Ret. Ass’n v. ViewRay, Inc., et al.

Parties and Procedural History. The original complaint was filed by a different plaintiff

on behalf of a putative class of purchasers of ViewRay’s common stock between March and

August 2019. As a member of the proposed class, Plymouth moved for (and was granted)

appointment as lead plaintiff; it then filed its first amended complaint on behalf of a differently

defined class (those who purchased ViewRay stock between May 10, 2018, and January 13, 2020).

In addition to suing ViewRay, Plymouth named several ViewRay officers (current and former) as

individual defendants; their identities are irrelevant for our purposes.

ViewRay moved to dismiss the first amended complaint for failure to state a claim; after

that motion was fully briefed, Plymouth moved for leave to amend the complaint again, which the

district court granted in a text-only order, and the second amended complaint (the “operative

complaint”) was docketed.

ViewRay moved to dismiss the operative complaint for failure to state a claim, arguing that

Plymouth failed to meet the heightened pleading standards for securities fraud under the Private

Securities Litigation Reform Act (“PSLRA”), Federal Rule of Civil Procedure 9(b), or both. The

district court agreed, granting the motion in a thorough and well-reasoned opinion and order. See

generally Plymouth Cnty. Ret. Ass’n v. ViewRay, Inc., 556 F. Supp. 3d 772, 791, 801–02 (N.D.

Ohio 2021). Plymouth now appeals.

II.

We review de novo an order granting a Rule 12(b)(6) motion to dismiss. Dougherty v.

Esperion Therapeutics, Inc., 905 F.3d 971, 978 (6th Cir. 2018). We construe the complaint in the

plaintiff’s favor and accept its well-pleaded factual allegations as true. City of Taylor Gen. Emps.

Ret. Sys. v. Astec Indus., Inc., 29 F.4th 802, 809 (6th Cir. 2022). Although our review is normally

limited to the complaint, we may also consider any document attached to the defendant’s motion

-3- No. 21-3863, Plymouth Cnty. Ret. Ass’n v. ViewRay, Inc., et al.

to dismiss if it “is referred to in the complaint and is central to the plaintiff’s claim.” Greenberg

v. Life Ins. Co. of Va., 177 F.3d 507, 514 (6th Cir. 1999) (citation omitted); see also In re Omnicare,

Inc. Sec. Litig., 769 F.3d 455, 466–67 (6th Cir. 2014).

To avoid dismissal, any complaint generally must “contain sufficient factual matter,

accepted as true, to ‘state a claim to relief that is plausible on its face.’” Ashcroft v. Iqbal, 556

U.S. 662, 678 (2009) (quoting Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570 (2007)). Securities-

fraud complaints like Plymouth’s, however, must clear a higher bar. The PSLRA stands as an

“elephant-sized boulder” to such suits and its “requirements are not easily satisfied.” Omnicare,

769 F.3d at 461. Along with Federal Rule of Civil Procedure 9(b), the PSLRA requires certain

elements of these claims (including both elements considered here) to be pleaded with

particularity. Astec Indus., 29 F.4th at 810, 812. At bottom, the plaintiff must “allege the ‘who,

what, where, when, and why’ of the fraudulent statements.” Id. at 810 (citation omitted).

III.

Count One of the operative complaint alleges that ViewRay violated Section 10(b) of the

Securities Exchange Act of 1934, 15 U.S.C.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Basic Inc. v. Levinson
485 U.S. 224 (Supreme Court, 1988)
Securities & Exchange Commission v. Zandford
535 U.S. 813 (Supreme Court, 2002)
Barnhart v. Thomas
540 U.S. 20 (Supreme Court, 2003)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Matrixx Initiatives, Inc. v. Siracusano
131 S. Ct. 1309 (Supreme Court, 2011)
Satish Doshi v. General Cable Corporation
823 F.3d 1032 (Sixth Circuit, 2016)
Kevin Dougherty v. Esperion Therapeutics
905 F.3d 971 (Sixth Circuit, 2018)

Cite This Page — Counsel Stack

Bluebook (online)
Cort Corwin v. ViewRay, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/cort-corwin-v-viewray-inc-ca6-2022.